Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oui Therapeutics, Inc.
With
National Institute of Mental Health (NIMH)
Florida State University
The purpose of this study is to conduct a randomized controlled trial to evaluate the efficacy of OTX-601 (intervention) compared to OTX-003 (comparator) in reducing PTSD symptoms from baseline to 7 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Posttraumatic stress disorder (PTSD) diagnosis
Anxiety Sensitivity Index 3 (ASI-3) scores above 24
PTSD Checklist for DSM-V (PCL-5) scores above 30
Understands and speaks English
Access to a smartphone that is connected to the internet
You may not be if
Score of 24 or lower on the ASI-3
Score of 30 and below on the PCL-5
No PTSD diagnosis
Active psychosis
Acute intoxication during study baseline
Enrolled in another treatment research study
Medical illness that would prevent the completion of interoceptive exposure exercises
Clareo Health | Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
